Navigation Links
Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
Date:12/17/2008

SAN FRANCISCO, Dec. 17 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it has completed patient enrollment in a Phase 1-2 dose-escalation clinical trial of MDV3100, its novel androgen receptor antagonist, in castration-resistant prostate cancer patients, and that it will seek approval from the U.S. Food and Drug Administration (FDA) to advance to Phase 3 clinical trials next year.

The open-label, U.S. Phase 1-2 study evaluated prostate cancer patients who had failed standard hormonal therapies, including men who had also failed standard chemotherapy regimens. A total of 140 men were enrolled in the trial, which evaluated doses between 30 and 600 mg/day. Patients are being followed and may remain on treatment for as long as they continue to tolerate the drug and their disease does not progress.

Preliminary results of this trial, covering 73 treated patients in the 60, 150 and 240 mg/day dose groups, were presented in October at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The data showed encouraging and durable anti-tumor activity as measured by prostate specific antigen (PSA) declines, radiographic findings, circulating tumor cell (CTC) changes and time on treatment. These data also suggested a dose-response trend, with a higher percentage of patients in the 240 mg/day dose group experiencing 90 percent reduction in PSA levels, radiographic partial responses and conversions to favorable CTC counts of less than five post-treatment.

The Company expects to move into Phase 3 trials with either the 240 or the 360 mg/day dose, both of which have been generally well tolerated. The 480 mg/day dose did not have acceptable tolerability due to side effects, primarily fatigue. Efficacy data from the 360 mg/day dose group are under analysis and wil
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
2. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
3. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
4. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
7. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
8. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
9. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
10. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
11. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014 /PRNewswire-iReach/ -- Inc. ... for the third straight year, No. 349 in ... exclusive ranking of the nation,s fastest-growing private companies. ... the most important segment of the economy—America,s independent ... Domino,s Pizza, LinkedIn, Zillow, and many other well-known ...
(Date:8/21/2014)... , Aug. 21, 2014 /PRNewswire-iReach/ -- ScriptPro has ... (HITRUST) under its Common Security Framework (CSF). According ... and Privacy Manager, "We appreciate this rigorous, top-to-bottom ... commitment that this certification signifies. Our business partners ... ABOUT THE CSF CERTIFICATION PROCESS: ScriptPro,s internal security ...
(Date:8/21/2014)... Aug. 21, 2014  Zacks.com announces the list of stocks ... Research analysts discuss the latest news and events impacting stocks ... include the Hewlett-Packard (NYSE: HPQ - Free Report ), IBM ... (NYSE: SB - Free Report ), GlaxoSmithKline plc (NYSE: ... (NYSE: FI - Free Report ). Today, ...
Breaking Medicine Technology:Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3ScriptPro Achieves HITRUST Certification 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 4The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 5The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 6The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 7The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 8The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 9The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 10The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 11
... 14 Spherix Incorporated,(Nasdaq: SPEX ) reported ... potential,type 2 diabetes drug, Naturlose(R), will expand outside ... of treatment-naive type II,diabetics are being considered. "This ... the first quarter of 2009, which is consistent ...
... a Safe and Effective ... Diabetes Patients, PHILADELPHIA, July 14 GlaxoSmithKline ... Drug Administration (FDA),updated the prescribing information for AVANDIA(R) ... Outcome Progression Trial,(ADOPT), a 4- to- 6 year ...
Cached Medicine Technology:Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U.S. 2FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years 2FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years 3
(Date:8/22/2014)... August 22, 2014 AWeber, one ... that currently helps more than 120,000 small businesses ... the attention of Shane Michaels, prompting an investigative review. ... element for any online marketing campaign, despite what some ... the marketing world,” reports Michaels. “AWeber is a great ...
(Date:8/22/2014)... MyWriters.com , an online source for ... for marketers to help them drive traffic to their ... Shane Michaels, prompting an investigative review. , “Anyone ... knows that content is king when it comes to ... even though content is extremely important, creating quality, original ...
(Date:8/22/2014)... This report studies the "Sample Preparation Market by ... Kits (Isolation, Purification), By Application (Genomics, Proteomics), by ... 2018" This market was valued at $4,254.8 million ... a CAGR of 5.9% from 2013 to 2018, ... 98 market data Tables and 23 Figures spread ...
(Date:8/22/2014)... Boston, Mass. (PRWEB) August 22, 2014 ... Chain Drug Stores (NACDS) Total Store Expo - which ... Boston Globe published a pro-pharmacy op-ed in its online ... medical care, enlist pharmacists ” is co-authored by Steven ... and Michael Malloy, PharmD, dean of the MCPHS University ...
(Date:8/22/2014)... Millennium Treatment Group has recently noticed an increase ... of drug use among teenagers. The treatment facility aims to ... work to minimize drug abuse. , America is currently seeing ... in history. According to the National Institute of Drug ... 12 or older—or 9.2 percent of the population—had used an ...
Breaking Medicine News(10 mins):Health News:AWeber: Review Exposes Affordable Provider of Opt-In Email Marketing Services 2Health News:My Writers: Review Exposes Online Source for Quality Marketing Content 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins 2Health News:The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins 3Health News:Millennium Treatment Group Sees Increase in Marijuana Use Among Youth 2
... passed on a rare side effect of the smallpox vaccination he ... , The boy who is currently being treated at University of ... percent of his body. ,Eczema vaccinatum is an unusual ... receive the shot or their close contacts. , The ...
... journal Proceedings of the National Academy of Sciences. The report ... in// preventing tuberculosis, and scientists may do well to resurrect ... led by Dr. Roland Brosch of the Institut Pasteur ... vaccines used in immunization of 2 million children around ...
... the first in the state to perform a novel ... regeneration of the heart muscle after a// heart attack. ... in the country providing this new treatment modality as ... a privately funded cell-therapy company studying stem cells for ...
... gene variants in Hispanic women are linked to spontaneous preterm ... Washington University.// ,The research was presented at the ... 16. ,Preterm birth is a major cause of ... birth was suggested by racial disparity, a tendency to occur ...
... have developed a procedure that estimates the reproductive potential ... multiple births and to achieve a higher success rate ... fertilization procedures are performed each year in the United ... in IVF cycles, but only 34.3 percent resulted in ...
... part of the body, could be an indicator of common ... development of new treatment. ,Zinc had previously been ... brains of patients with Alzheimer's disease. It is also vital ... ,Zinc is particularly important for healthy skin and ...
Cached Medicine News:Health News:Toddler Infected With Rare Side Effect of Smallpox Vaccine 2Health News:TB Vaccines: Ring Out the New, Bring in the Old 2Health News:Vanderbilt Performs State's First Stem Cell Heart Regeneration Therapy 2Health News:Vanderbilt Performs State's First Stem Cell Heart Regeneration Therapy 3Health News:Gene Variants Linked to Preterm Birth in Hispanic Women 2
... Our one-of-kind Expander ... solve the problem of ... fit. The Expander Sizer™ ... perfect solution to post ...
For lipoplasty of trochanteric area, abdomen, thighs, hips, buttocks and flanks...
Black Spandex Above the Knee Compression Girdles with Contact Closure with Zipper...
Short Girdle, High Waist, Mid-thigh...
Medicine Products: